{"entity":{"id":"nct06162572","kind":"trial","name":"Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)","aka":[],"tldr":"A phase 1/2 trial of Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by Servier Bio-Innovation LLC, active and no longer recruiting.","summary":"Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 1/2 interventional study registered as NCT06162572 by Servier Bio-Innovation LLC, with 102 participants enrolled, started 2024-08-07 and due to reach its primary completion in 2027-04. Interventions recorded: S095018, S095024, S095029, S095018 Recommended Dose Expansion (RDE), S095024 RDE. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06162572","url":"https://clinicaltrials.gov/study/NCT06162572"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","pdl1-high-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["cemiplimab"],"companies":["servier"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06162572","phase":"1/2","setting":"A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression","sponsor":"Servier Bio-Innovation LLC","started":"2024-08-07","startedType":"actual","enrolled":102,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06162572/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"}],"company":[{"id":"servier","kind":"company","name":"Servier","route":"/companies/servier/"}]}}